About Elucid Bioimaging
Elucid Bioimaging is a pioneering medical technology company that leverages artificial intelligence (AI) and quantitative analysis to provide physicians with advanced imaging analysis software for cardiovascular disease. Their core mission is to predict and personalize the prevention of heart attacks and strokes by offering a more precise view of atherosclerosis, the root cause of cardiovascular disease. The company’s flagship product, Plaque-IQ™, is an FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies and characterizes plaque morphology, validated against ground-truth histology—the gold standard for plaque characterization.
Elucid’s platform transforms standard CT images into a dynamic, interactive map of disease, enabling clinicians to assess plaque composition, coronary blockages, and ischemia risk. This technology aims to move cardiovascular care from population-based treatment towards personalized diagnosis and treatment decisions. In addition to Plaque-IQ™, Elucid also offers FFR-IQ™ software, which provides noninvasive assessment of coronary physiology (FFR-CT) derived from their plaque analysis, integrating anatomy, plaque biology, and physiology to help identify coronary blockages and the extent of ischemia. The company’s solutions are designed to support health systems, cardiologists, radiologists, and vascular specialists, with a focus on improving patient outcomes and reducing costs.
Focus Areas
Business Intelligence
| Technology | Cloud-native, AI operating system, machine learning, patented computer algorithms based on histological data, DICOM-wrapped PDFs, interactive browser-based reports |
What Physicians Need to Know
Elucid's technology offers physicians a comprehensive platform for personalized cardiovascular care. The Plaque-IQ software provides histology-validated quantitative plaque analysis, including the identification of high-risk Lipid Rich Necrotic Core (LRNC), which is crucial for assessing heart attack and stroke risk. The FFR-IQ software offers a BioIntegrated FFR-CT that considers both anatomy and plaque composition for more accurate physiological assessment of coronary blockages. This integrated approach allows for lesion-specific assessment and supports more informed treatment decisions, potentially reducing unnecessary invasive procedures. The ability to analyze both coronary and carotid arteries from a single CCTA scan provides a holistic view of systemic atherosclerotic risk. Furthermore, Elucid's technology is designed to be transparent and reproducible, offering detailed insights beyond traditional stenosis assessment. The recent Category I CPT code for quantitative coronary plaque analysis (75577) and expanding reimbursement coverage also make this technology more accessible.
Elucid's software works with all CTA scanners using standard acquisition protocols. The platform supports DICOM integration and PACS/EMR interoperability for seamless integration into clinical workflows. While Elucid does not publish a public developer program, API reference, or SDK, their product is delivered as an end-user clinical platform.
What the Web Says
Elucid Bioimaging offers an AI-powered SaaS platform, PlaqueIQ, for cardiovascular disease assessment, which analyzes coronary CT angiography to quantify plaque and identify high-risk features. The company has received FDA clearance for PlaqueIQ and recently for its FFR-IQ software, and has secured significant funding. Employee reviews indicate mixed sentiments regarding management and culture, with some concerns about ageism, while product reviews highlight its histology-validated approach and utility for clinicians.
Overall: MixedStrengths
- PlaqueIQ is FDA-cleared and histology-validated, providing accurate plaque analysis.
- The PlaqueIQ tool helps clinicians assess cardiovascular disease, quantify plaque, and identify high-risk features.
- Plaque analysis using Elucid's software is reimbursable with a dedicated CPT code.
- The company's FFR-IQ software provides a noninvasive estimate of fractional flow reserve, enhancing diagnostic capabilities.
- Elucid's technology allows for detailed, lesion-level plaque inspection, aiding in personalized treatment.
- Good work-life balance and job security reported by some employees.
Limitations
- Some employee reviews mention issues with management and company culture.
- Concerns about ageism have been raised by former employees.
- The product workflow involves trained human analysts, meaning results are not instant.
- No published studies directly evaluate PlaqueIQ, with trade coverage primarily from the vendor.
- Lack of EHR or PACS integration, and no HIPAA, SOC 2, or HITRUST attestation listed.
- Competitors like HeartFlow and Cleerly offer similar plaque analysis tools, with no head-to-head data on accuracy or turnaround.
Based on reviews from: jobtoday.com, indeed.com, simplyhired.com, simplify.jobs, medaiverdict.com, elucid.com, massdevice.com, medtechdive.com, yespress.io, slashdot.org, elion.health
Last updated: 2026-10-26
Videos
News, demos, and interviews about Elucid Bioimaging.
Videos load interactively. If none appear, search YouTube for Elucid Bioimaging →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]